Omnicell Q2 revenue up 5%, hikes FY forecast
Overview
Omnicell Q2 2025 revenue rises 5% yr/yr to $291 mln, driven by connected devices
Company exceeds guidance for non-GAAP EBITDA and EPS, reflecting strong performance
Omnicell raises full-year 2025 guidance for total revenues, non-GAAP EBITDA, and EPS
Outlook
Omnicell raises full-year 2025 revenue guidance to $1.130 bln - $1.160 bln
Company expects Q3 2025 revenue between $290 mln and $300 mln
Omnicell sees full-year non-GAAP EPS at $1.40 - $1.65
Company forecasts Q3 non-GAAP EPS at $0.30 - $0.37
Company forecasts Q3 non-GAAP EBITDA of $28 mln - $32 mln
Result Drivers
CONNECTED DEVICES - Strong demand for XT Series automated dispensing cabinets and XTExtend console drove revenue growth
NEW PRODUCTS - Introduction of MedTrack RFID Line and MedVision inventory management solution contributed to results
REVENUE DRIVERS - Growth in connected devices, technical services, SaaS and Expert Services, and consumables revenues fueled revenue increase
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | $291 mln | ||
Q2 Adjusted Net Income | $21 mln | ||
Q2 Net Income | $6 mln | ||
Q2 Adjusted EBITDA | $38 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Omnicell Inc is $44.00, about 32.5% above its July 30 closing price of $29.70
The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 19 three months ago
Press Release:
